SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Down 32.1% in November

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 39,900 shares, a decline of 32.1% from the October 31st total of 58,800 shares. Based on an average trading volume of 74,700 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SABS. Oppenheimer reissued an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Finally, Craig Hallum initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Trading Down 1.0 %

Shares of SABS traded down $0.03 during midday trading on Friday, hitting $2.92. The company’s stock had a trading volume of 56,852 shares, compared to its average volume of 75,648. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $9.72. The company’s fifty day simple moving average is $2.99 and its two-hundred day simple moving average is $2.90.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. Equities analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank acquired a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned about 0.21% of SAB Biotherapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.